ARTICLE | Clinical News
Oncoprex: Interim Ph II data
January 27, 2017 4:30 AM UTC
Interim data from 9 evaluable patients with stage IV NSCLC who failed ≥2 treatment regimens in an open-label, U.S. Phase II trial showed that IV Oncoprex every 3 weeks plus Tarceva erlotinib led to a ...
BCIQ Company Profiles
BCIQ Target Profiles